JP2012501959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501959A5 JP2012501959A5 JP2010523608A JP2010523608A JP2012501959A5 JP 2012501959 A5 JP2012501959 A5 JP 2012501959A5 JP 2010523608 A JP2010523608 A JP 2010523608A JP 2010523608 A JP2010523608 A JP 2010523608A JP 2012501959 A5 JP2012501959 A5 JP 2012501959A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- immunogenic composition
- antigens
- ypo0499
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 631
- 102000036639 antigens Human genes 0.000 claims description 631
- 108091007433 antigens Proteins 0.000 claims description 631
- 230000002163 immunogen Effects 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 75
- 230000028993 immune response Effects 0.000 claims description 29
- 241000124008 Mammalia Species 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 101100294224 Yersinia pestis nlpI gene Proteins 0.000 claims description 9
- 101100493693 Yersinia pestis bamC gene Proteins 0.000 claims description 6
- 101100116909 Yersinia pestis djlA gene Proteins 0.000 claims description 6
- 101100421109 Yersinia pestis secM gene Proteins 0.000 claims description 6
- 101100381447 Yersinia pestis bamA gene Proteins 0.000 claims description 4
- 101100440427 Yersinia pestis coaE gene Proteins 0.000 claims description 4
- 101100064180 Yersinia pestis dsbA gene Proteins 0.000 claims description 4
- 101100281900 Yersinia pestis fyuA gene Proteins 0.000 claims description 4
- 101100220525 Yersinia pestis groEL gene Proteins 0.000 claims description 4
- 101100126385 Yersinia pestis ispD gene Proteins 0.000 claims description 4
- 101100188657 Yersinia pestis ompA gene Proteins 0.000 claims description 4
- 101100060882 Yersinia pestis pla gene Proteins 0.000 claims description 4
- 101100475179 Yersinia pestis rpsC gene Proteins 0.000 claims description 4
- 101100093726 Yersinia pestis rpsD gene Proteins 0.000 claims description 4
- 101100365859 Yersinia pestis skp gene Proteins 0.000 claims description 4
- 101100478915 Yersinia pestis surA gene Proteins 0.000 claims description 4
- 101100118435 Yersinia pestis tufA gene Proteins 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 101100170819 Yersinia pestis dnaK gene Proteins 0.000 claims description 3
- 101100472136 Yersinia pestis rplI gene Proteins 0.000 claims description 3
- 101100207359 Yersinia pestis tpx gene Proteins 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 16
- 238000003491 array Methods 0.000 claims 1
- 101100393774 Yersinia pestis hemL gene Proteins 0.000 description 3
- 101100256513 Yersinia pestis secB gene Proteins 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0717187.9A GB0717187D0 (en) | 2007-09-04 | 2007-09-04 | Compositions comprising yersinia pestis antigens |
| PCT/IB2008/003081 WO2009031043A2 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising yersinia pestis antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012501959A JP2012501959A (ja) | 2012-01-26 |
| JP2012501959A5 true JP2012501959A5 (enExample) | 2012-10-11 |
Family
ID=38640215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523608A Pending JP2012501959A (ja) | 2007-09-04 | 2008-09-04 | Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100183674A1 (enExample) |
| EP (1) | EP2205274A2 (enExample) |
| JP (1) | JP2012501959A (enExample) |
| AU (1) | AU2008294413A1 (enExample) |
| CA (1) | CA2698360A1 (enExample) |
| GB (1) | GB0717187D0 (enExample) |
| WO (1) | WO2009031043A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| PL2590676T3 (pl) | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| RS63315B1 (sr) | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| JP5908477B2 (ja) | 2010-08-31 | 2016-04-26 | ノバルティス アーゲー | タンパク質をコードするｒｎａのリポソームによる送達に適した脂質 |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| EP2667852B1 (en) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with crystallisation inhibitors |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| SG10201602456WA (en) | 2011-08-31 | 2016-04-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| PT3083556T (pt) | 2013-12-19 | 2020-03-05 | Novartis Ag | Lípidos e composições lipídicas para a entrega de agentes ativos |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| JP6731912B2 (ja) | 2014-09-05 | 2020-07-29 | ノバルティス アーゲー | 活性物質の送達用の脂質および脂質組成物 |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US20220218622A1 (en) | 2020-10-14 | 2022-07-14 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| US20250134824A1 (en) | 2021-08-16 | 2025-05-01 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2215203C (en) * | 1995-03-13 | 2008-12-09 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Vaccines for plague |
| EP1954306A2 (en) * | 2005-10-25 | 2008-08-13 | Novartis Vaccines and Diagnostics S.r.l. | Compositions comprising yersinia pestis antigens |
-
2007
- 2007-09-04 GB GBGB0717187.9A patent/GB0717187D0/en not_active Ceased
-
2008
- 2008-09-04 JP JP2010523608A patent/JP2012501959A/ja active Pending
- 2008-09-04 US US12/733,488 patent/US20100183674A1/en not_active Abandoned
- 2008-09-04 WO PCT/IB2008/003081 patent/WO2009031043A2/en not_active Ceased
- 2008-09-04 EP EP08829437A patent/EP2205274A2/en not_active Withdrawn
- 2008-09-04 AU AU2008294413A patent/AU2008294413A1/en not_active Abandoned
- 2008-09-04 CA CA2698360A patent/CA2698360A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501959A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| CA2187083C (fr) | Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation | |
| JP2022023102A (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2009515831A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2007505033A5 (enExample) | ||
| JP2018509935A5 (enExample) | ||
| JP2012523246A5 (enExample) | ||
| CN105792842A (zh) | 埃巴病毒疫苗 | |
| JP2014507146A5 (enExample) | ||
| JP2015529678A5 (enExample) | ||
| CA2789483A1 (en) | Novel hiv-1 envelope glycoprotein | |
| JP2013504556A5 (enExample) | ||
| JP2015505309A5 (enExample) | ||
| JP6676661B2 (ja) | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 | |
| JP2012525410A5 (enExample) | ||
| JP2015500827A5 (enExample) | ||
| JP2013545448A5 (enExample) | ||
| Li et al. | Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system | |
| US11352411B2 (en) | Fusion peptides of CD4 helper T cell epitopes and vaccines thereof | |
| JP2012516140A5 (enExample) | ||
| WO2022127825A1 (zh) | 针对新型冠状病毒感染的疫苗组合物 | |
| ES2236718T3 (es) | Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna. | |
| Valmori et al. | Induction of a cytotoxic T cell response by co‐injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre‐injection of IFA alone |